Adelphi Group (United Kingdom)

Describing Patient Characteristics, Treatment Patterns, and Disease Burden Among Patients with Alopecia Areata in Mexico: A Secondary Analysis of the Adelphi Real World Alopecia Areata Disease Specific Programme

Alopecia areata (AA) is a common autoimmune disease characterized by nonscarring hair loss, yet real-world data on AA in Mexico are sparse. This study aimed to characterize disease burden and identify unmet treatment needs among patients with AA in Mexico. Clinical data were anal...

Real-world clinical experience with ruxolitinib cream versus systemic therapies in patients with moderate atopic dermatitis in the United States

PURPOSE: Ruxolitinib cream (Janus kinase [JAK]1/JAK2 inhibitor) was effective and well tolerated in clinical trials of patients with atopic dermatitis (AD). We examined real-world outcomes among patients with moderate AD treated with ruxolitinib cream or systemic therapies. METHO...

Patient perspectives from the BEYOND Delphi panel: burden of remaining symptoms and their fluctuations, despite treatment, in patients with generalised myasthenia gravis

Abstract Background Patients with generalised myasthenia gravis (gMG) can experience remaining symptoms despite treatment. Our study aimed to describe how remaining symptoms and their fluctuations may affect a person’s daily life while living with gMG. Methods A modified-Delphi p...

Evolution of treatment distribution and patient characteristics of muscle invasive bladder cancer patients: results from two multi-national real-world surveys

To describe the real-world clinical characteristics and treatment distribution of patients with muscle-invasive bladder cancer (MIBC), and to discuss how these patterns have evolved over time. Data were drawn two separate cohorts of the Adelphi Muscle Invasive Urothelial Cancer D...